Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

​Monday’s Biotech Madness: 3 Stocks on Tap Including Ardelyx

Now that biotech companies will make acquisitions to strengthen research and development instead of for lower tax reasons, these biotech stocks are on watch:

1)ARDX – Ardelyx – $4.19/sh book value and $3.09 / sh in cash. Company makes GI therapies. Last quarter, it lost $17M on 0 revenue. R&D spend in 2015 was $39.9M

2)Medivation – MDVN – has an $7.6B market cap. Makes drugs for prostate cancer

3)Relypsa – RLYP –market cap is around $1B and is up on buyout rumors. Shorts lead the narrative by covering the short in the teens and buying as the stock benefits from unsubstantiated buyout rumors. Beware.